The Wall Street Journal reports Pfizer hopes to market a new version of the blockbuster cholesterol drug after the original one loses its patent in November, and cheaper generic versions go on sale. Not everyone is excited about the idea – one cardiologist told us she worries that patients will not get the right dosage amount without the supervision of a doctor.